OptiNose, Inc. (OPTN)
After hours:
| Previous close | 0.8776 |
| Open | 0.8799 |
| Bid | 0.9943 x 200 |
| Ask | 1.0200 x 1000 |
| Day's range | 0.8799 - 1.0100 |
| 52-week range | 0.8000 - 2.1000 |
| Volume | |
| Avg. volume | 1,082,266 |
| Market cap | 114.169M |
| Beta (5Y monthly) | -0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3200 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.75 |
ZacksWill Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksWill OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireOptinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern TimeYARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps
